Overview

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Bausch Health Americas, Inc.
Treatments:
Antibodies, Monoclonal
Brodalumab